The Malignancy Panel (MALE) offered by MedEx Neo Clinic is a comprehensive set of tests designed to screen for and detect potential male malignancies. This panel includes a range of tumor markers to help identify certain types of cancers and monitor their progression.
The panel includes the following tests:
Alpha-Fetoprotein (AFP): This test measures the levels of AFP, a tumor marker associated with liver and certain testicular cancers. Elevated levels of AFP may indicate the presence of these malignancies.
Beta HCG: This test measures the levels of beta human chorionic gonadotropin (HCG), a hormone produced by certain cancer cells, including testicular cancer. Elevated beta HCG levels can indicate testicular or other germ cell tumors.
CA 19.9: This test measures the levels of carbohydrate antigen 19.9 (CA 19.9), which is associated with gastrointestinal cancers, particularly pancreatic cancer. Monitoring CA 19.9, levels can help detect or monitor the progression of these malignancies.
CEA (Carcinoembryonic Antigen): This test measures the levels of CEA, a tumor marker commonly associated with colorectal cancer. Elevated levels of CEA may indicate the presence of colorectal cancer or the recurrence of the disease.
PSA (Prostate-Specific Antigen): This test measures the levels of PSA, a protein produced by the prostate gland. Elevated PSA levels may indicate prostate conditions, including prostate cancer. Monitoring PSA levels helps in the early detection and management of prostate cancer.
The Malignancy Panel (MALE) provided by MedEx Neo Clinic aims to screen for and detect potential male malignancies by measuring specific tumor markers associated with various types of cancers. It assists in early detection, monitoring, and providing appropriate guidance for further evaluation and management. The exact pricing for the panel can be obtained directly from MedEx Neo Clinic, as it may vary based on location and specific offerings.